Ana Maria Rivas-Grajales, MD

Assistant Professor, Psychiatry

Ana Rivas-Grajales


Dr. Ana Maria Rivas-Grajales is a Neuropsychiatrist and Assistant Professor in the Department of Psychiatry at Boston University Chobanian & Avedisian School of Medicine. Dr. Rivas-Grajales completed residency training in psychiatry at Baylor College of Medicine, and a clinical fellowship in Behavioral Neurology and Neuropsychiatry at Massachusetts General Hospital. She currently serves as the Director of the Transcranial Magnetic Stimulation Clinic at Boston Medical Center, where she provides care to patients with major depressive disorder. Her clinical expertise include neuropsychiatric complications of movement disorders, dementia, epilepsy and functional neurological disorder. Her research focuses on understanding of the mechanism of action of neuromodulation therapies for treatment-resistant depression, and identifying clinical and imaging biomarkers of rapid-acting antidepressants.


  • Universidad Del Valle, MD
  • University College London (UCL), MSc


  • Published on 12/19/2023

    Tanev KS, Camprodon JA, Caplan DN, Dickerson BC, Chemali Z, Eldaief MC, Kim DD, Josephy-Hernandez SE, Kritzer MD, Moo LR, Newhouse A, Perez DL, Ramirez Gomez LA, Razafsha M, Rivas-Grajales AM, Scharf JM, Schmahmann JD, Sherman JC. Telemedicine-Based Cognitive Examinations During COVID-19 and Beyond: Perspective of the Massachusetts General Hospital Behavioral Neurology & Neuropsychiatry Group. J Neuropsychiatry Clin Neurosci. 2024; 36(2):87-100. PMID: 38111331.

    Read at: PubMed
  • Published on 5/1/2023

    Rivas-Grajales AM, Barbour T, Camprodon JA, Kritzer MD. The Impact of Sex Hormones on Transcranial Magnetic Stimulation Measures of Cortical Excitability: A Systematic Review and Considerations for Clinical Practice. Harv Rev Psychiatry. 2023 May-Jun 01; 31(3):114-123. PMID: 37171472.

    Read at: PubMed
  • Published on 1/1/2023

    Carreon RL, Rivas-Grajales AM, Murphy N, Mathew SJ, Jha MK. Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics. Adv Neurobiol. 2023; 30:287-297. PMID: 36928855.

    Read at: PubMed
  • Published on 1/1/2022

    Molton IR, Keatley E, Jaywant A, Josephy-Hernandez S, Rivas-Grajales AM, Perez DL, Mukherjee D. Ethical issues in the treatment of functional neurological disorder. PM R. 2022 01; 14(1):112-119. PMID: 34958180.

    Read at: PubMed
  • Published on 11/5/2021

    Rivas-Grajales AM, Mathew SJ, Rodgers JJ. A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. J Psychiatr Pract. 2021 11 05; 27(6):492-495. PMID: 34768275.

    Read at: PubMed
  • Published on 5/18/2021

    Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391. PMID: 33249434.

    Read at: PubMed
  • Published on 10/28/2019

    Schanzer B, Rivas-Grajales AM, Khan A, Mathew SJ. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012. PMID: 31607187.

    Read at: PubMed
  • Published on 6/16/2019

    Mathew SJ, Rivas-Grajales AM. "Does the opioid system block or enhance the antidepressant effects of ketamine?" Chronic Stress (Thousand Oaks). 2019 Jan-Dec/; 3. PMID: 31276079.

    Read at: PubMed
  • Published on 6/1/2016

    Kanner AM, Rivas-Grajales AM. Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. CNS Spectr. 2016 Jun; 21(3):247-57. PMID: 27322691.

    Read at: PubMed

View all profiles